Hierarchical clustering of PI3K and MAPK pathway proteins in breast cancer intrinsic subtypes

por Kruger, Dinja T., Opdam, Mark, Sanders, Joyce, van der Noort, Vincent, Boven, Epie, Linn, Sabine C.
Publicado 2020

Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences

por Kruger, Dinja T., Beelen, Karin J., Opdam, Mark, Sanders, Joyce, van der Noort, Vincent, Boven, Epie, Linn, Sabine C.
Publicado 2018

PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy

por Beelen, Karin, Hoefnagel, Laurien DC, Opdam, Mark, Wesseling, Jelle, Sanders, J, Vincent, Andrew D, van Diest, Paul J, Linn, Sabine C
Publicado 2014

Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot

por Beelen, Karin, Opdam, Mark, Severson, Tesa, Koornstra, Rutger, Vincent, Andrew, Wesseling, Jelle, Sanders, Joyce, Vermorken, Jan, van Diest, Paul, Linn, Sabine
Publicado 2018

IGF‐1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER‐positive breast cancer

por Kruger, Dinja T., Alexi, Xanthippi, Opdam, Mark, Schuurman, Karianne, Voorwerk, Leonie, Sanders, Joyce, van der Noort, Vincent, Boven, Epie, Zwart, Wilbert, Linn, Sabine C.
Publicado 2019

PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane

por Kruger, Dinja T., Opdam, Mark, van der Noort, Vincent, Sanders, Joyce, Nieuwenhuis, Michiel, de Valk, Bart, Beelen, Karin J., Linn, Sabine C., Boven, Epie
Publicado 2020

BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer

por Lips, Esther H., Benard-Slagter, Anne, Opdam, Mark, Scheerman, Caroline E., Wesseling, Jelle, Hogervorst, Frans B. L., Linn, Sabine C., Savola, Suvi, Nederlof, Petra M.
Publicado 2020

Deep learning-based breast cancer grading and survival analysis on whole-slide histopathology images

por Wetstein, Suzanne C., de Jong, Vincent M. T., Stathonikos, Nikolas, Opdam, Mark, Dackus, Gwen M. H. E., Pluim, Josien P. W., van Diest, Paul J., Veta, Mitko
Publicado 2022

Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Rep...

por Szijgyarto, Zsolt, Flach, Koen D., Opdam, Mark, Palmieri, Carlo, Linn, Sabine C., Wesseling, Jelle, Ali, Simak, Bliss, Judith M., Cheang, Maggie Chon U., Zwart, Wilbert, Coombes, R. Charles
Publicado 2019

PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenop...

por Beelen, Karin, Opdam, Mark, Severson, Tesa M, Koornstra, Rutger HT, Vincent, Andrew D, Wesseling, Jelle, Muris, Jettie J, Berns, Els MJJ, Vermorken, Jan B, van Diest, Paul J, Linn, Sabine C
Publicado 2014

Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment

por Beelen, Karin, Opdam, Mark, Severson, Tesa M, Koornstra, Rutger HT, Vincent, Andrew D, Wesseling, Jelle, Muris, Jettie J, Berns, Els MJJ, Vermorken, Jan B, van Diest, Paul J, Linn, Sabine C
Publicado 2014

Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients

por de Boo, Leonora W., Jóźwiak, Katarzyna, Joensuu, Heikki, Lindman, Henrik, Lauttia, Susanna, Opdam, Mark, van Steenis, Charlaine, Brugman, Wim, Kluin, Roelof J. C., Schouten, Philip C., Kok, Marleen, Nederlof, Petra M., Hauptmann, Michael, Linn, Sabine C.
Publicado 2022

Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system

por Klarenbeek, Sjoerd, Doornebal, Chris W., Kas, Sjors M., Bonzanni, Nicola, Bhin, Jinhyuk, Braumuller, Tanya M., van der Heijden, Ingrid, Opdam, Mark, Schouten, Philip C., Kersten, Kelly, de Bruijn, Roebi, Zingg, Daniel, Yemelyanenko, Julia, Wessels, Lodewyk F.A., de Visser, Karin E., Jonkers, Jos
Publicado 2020

Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer

por De Marchi, Tommaso, Timmermans, Anne M., Smid, Marcel, Look, Maxime P., Stingl, Christoph, Opdam, Mark, Linn, Sabine C., Sweep, Fred C. G. J., Span, Paul N., Kliffen, Mike, van Deurzen, Carolien H. M., Luider, Theo M., Foekens, John A., Martens, John W., Umar, Arzu
Publicado 2015

Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes

por Sobral-Leite, Marcelo, Salomon, Izhar, Opdam, Mark, Kruger, Dinja T., Beelen, Karin J., van der Noort, Vincent, van Vlierberghe, Ronald L. P., Blok, Erik J., Giardiello, Daniele, Sanders, Joyce, Van de Vijver, Koen, Horlings, Hugo M., Kuppen, Peter J. K., Linn, Sabine C., Schmidt, Marjanka K., Kok, Marleen
Publicado 2019

4‐protein signature predicting tamoxifen treatment outcome in recurrent breast cancer

por De Marchi, Tommaso, Liu, Ning Qing, Stingl, Cristoph, Timmermans, Mieke A., Smid, Marcel, Look, Maxime P., Tjoa, Mila, Braakman, Rene B.H., Opdam, Mark, Linn, Sabine C., Sweep, Fred C.G.J., Span, Paul N., Kliffen, Mike, Luider, Theo M., Foekens, John A., Martens, John W.M., Umar, Arzu
Publicado 2015

Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy

por van Rossum, Annelot G.J., Kok, Marleen, McCool, Danielle, Opdam, Mark, Miltenburg, Nienke C., Mandjes, Ingrid A.M., van Leeuwen-Stok, Elise, Imholz, Alex L.T., Portielje, Johanneke E.A., Bos, Monique M.E.M., van Bochove, Aart, van Werkhoven, Erik, Schmidt, Marjanka K., Oosterkamp, Hendrika M., Linn, Sabine C.
Publicado 2017

MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer

por Bhin, Jinhyuk, Yemelyanenko, Julia, Chao, Xue, Klarenbeek, Sjoerd, Opdam, Mark, Malka, Yuval, Hoekman, Liesbeth, Kruger, Dinja, Bleijerveld, Onno, Brambillasca, Chiara S., Sprengers, Justin, Siteur, Bjørn, Annunziato, Stefano, van Haren, Matthijs J., Martin, Nathaniel I., van de Ven, Marieke, Peters, Dennis, Agami, Reuven, Linn, Sabine C., Boven, Epie, Altelaar, Maarten, Jonkers, Jos, Zingg, Daniel, Wessels, Lodewyk F.A.
Publicado 2023

Long-term prognosis of young breast cancer patients (≤40 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study

por Dackus, Gwen MHE, ter Hoeve, Natalie D, Opdam, Mark, Vreuls, Willem, Varga, Zsuzsanna, Koop, Esther, Willems, Stefan M, Van Deurzen, Carolien HM, Groen, Emilie J, Cordoba, Alicia, Bart, Jos, Mooyaart, Antien L, van den Tweel, Jan G, Zolota, Vicky, Wesseling, Jelle, Sapino, Anna, Chmielik, Ewa, Ryska, Ales, Amant, Frederic, Broeks, Annegien, Kerkhoven, Ron, Stathonikos, Nikolas, Veta, Mitko, Voogd, Adri, Jozwiak, Katarzyna, Hauptmann, Michael, Hoogstraat, Marlous, Schmidt, Marjanka K, Sonke, Gabe, van der Wall, Elsken, Siesling, Sabine, van Diest, Paul J, Linn, Sabine C
Publicado 2017

Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments

por Kester, Lennart, Seinstra, Danielle, van Rossum, Annelot G.J., Vennin, Claire, Hoogstraat, Marlous, van der Velden, Daphne, Opdam, Mark, van Werkhoven, Erik, Hahn, Kerstin, Nederlof, Iris, Lips, Ester H., Mandjes, Ingrid A.M., van Leeuwen-Stok, A. Elise, Canisius, Sander, van Tinteren, Harm, Imholz, Alex L.T., Portielje, Johanneke E.A., Bos, Monique E.M.M., Bakker, Sandra D., Rutgers, Emiel J., Horlings, Hugo M., Wesseling, Jelle, Voest, Emile E., Wessels, Lodewyk F.A., Kok, Marleen, Oosterkamp, Hendrika M., van Oudenaarden, Alexander, Linn, Sabine C., van Rheenen, Jacco
Publicado 2022